Testing effectiveness (Phase 2)Study completedNCT04594005What this trial is testingCDK4/6 Tumor, Abemaciclib, PaclitaxelWho this might be right forTumors Yonsei University 30
Early research (Phase 1)Study completedNCT03434262What this trial is testingSJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain TumorsWho this might be right forAnaplastic AstrocytomaAnaplastic EpendymomaAnaplastic Ganglioglioma+53 more St. Jude Children's Research Hospital 68
Testing effectiveness (Phase 2)Looking for participantsNCT06363734What this trial is testingOsimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II TrialWho this might be right forNon-small Cell Lung CancerEGFR Activating MutationCell Cycle Deregulation+1 more Tianjin Medical University Cancer Institute and Hospital 32
Testing effectiveness (Phase 2)Active Not RecruitingNCT05039177What this trial is testingERAS-007 in Patients With Advanced Gastrointestinal MalignanciesWho this might be right forMetastatic Colorectal CancerMetastatic Pancreatic Ductal Adenocarcinoma Erasca, Inc. 102
Testing effectiveness (Phase 2)Study completedNCT02187783What this trial is testingLEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)Who this might be right forTumors With CDK4/6 Pathway Activation Novartis Pharmaceuticals 106